Tokyo

London

New York

finscreener facebook fan page

finscreener twitter page

finscreener linkedin page

finscreener stocktwits page

Novelion Therapeutics Inc.

NASDAQ: NVLNHealthcare / Biotechnology / Canada
0.9700-0.0100-1.02%Vol 128 5991Y Perf -74.93%
Jan 18th, 2019 15:36
BID0.9700 ASK0.9900
Open1.00 Previous Close0.9900
Pre-Market- After-Trading-
 - -%  - -%
Target Price
6.50 
Analyst Rating
Hold 3.00
Potencial %
570.10 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
     30.28
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
     35.47
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
 —    -
Market Cap (mil)18 
Earnings Rating
Neutral
Price Range Ratio 52wk %
5.22 
Earnings Date
8th Nov 2018

Today's Price Range

0.96001.02

 

52wk Range

0.70005.87

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Month
-1.02%
3 Months
-5.83%
6 Months
-71.64%
1 Year
-74.93%
3 Years
-92.39%
5 Years
-97.07%

Quotes

Name / TickerPriceChg.Chg.%
NVLN0.9700-0.0100-1.02
AAPL156.820.96000.62
GOOG1 098.268.36000.77
MSFT107.711.59001.50
XOM72.990.86001.19
WFC50.010.78001.58
JNJ130.691.60001.24
FB150.041.74001.17
GE9.06-0.0800-0.88
JPM104.591.67001.62
Financial StrengthValueIndustryS&P 500US Markets
Quick Ratio
0.10
Current Ratio
0.20
Long Term Debt to Total Capital
0.95
Total Debt to Equity
17.31
Interest Coverage
-9.30
Leverage Ratio -8.00
ProfitabilityValueIndustryS&P 500US Markets
Gross Margin
54.30
EBIT Margin
-48.90
EBITDA Margin
-27.90
Pre-tax Profit Margin
-
Profit Margin
-99.08
ValuationValueIndustryS&P 500US Markets
PE Ratio
-
PB Ratio
5.37
PS Ratios
0.22
Price to Cash Flow
33.20
Price to Free Cash Flow
-0.40
Cash Flow Per Share
-3.31
Price to Tangible Book
-0.07
Book Value per Share
-3.65
Enterprise Value (in ths.)
295 519
Management EffectivenessValueIndustryS&P 500US Markets
Return on Equity (5Y Avg)
-29.19
ROE last 12 Months
733.91
Return on Assets (5Y Avg)
-12.63
ROA last 12 Months
-30.95
Return on Capital (5Y Avg)
-22.48
ROC last 12 Months
-8.08
Return on invested Capital Q
-8.08
Return on invested Capital Y
-39.92
Assets Turnover
0.10
Receivables Turnover
1.20
RevenueValueIndustryS&P 500US Markets
Revenue LTM (in ths.)
89 722
Revenue per Share
4.74
Revenue Growth 3 Years
-
Revenue Growth 5 Years
-
DividendsValueIndustryS&P 500US Markets
Dividend Yield
-
Dividend Rate
-
Dividend Growth 3 Years
-
Dividend Growth 5 Years
-

Earnings HistoryEstimateReportedSurprise %
Q03 2018--1.32-
Q02 2018--0.64-
Q01 2018--1.76-
Q04 2017-1.58-1.3216.46
Q03 2017-0.29-0.89-206.90
Q02 2017-0.09-0.13-44.44
Q01 2017-0.47-0.54-14.89
Q04 2016-0.50-1.76-252.00
Earnings Per EndEstimateRevision %Trend
12/2017 QR-2.23-36.81Negative
12/2018 QR-0.9085.44Positive
12/2018 FY-5.6311.34Positive
12/2019 FY-3.64--
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume128 599
Shares Outstanding (in ths.)18 932
Trades Count138
Dollar Volume114 327
Avg. Volume241 377
Avg. Weekly Volume275 840
Avg. Monthly Volume287 680
Avg. Quarterly Volume2 076 305

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

48%52%

Bearish Bullish

56%44%

Bearish Bullish

49%51%

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
1 (100.00 %)
Hold
1 (100.00 %)
1 (100.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingHold
3.00
Hold
3.00
Moderate Buy
2.00

There are no comments yet.

News